1. Rinehart KL, Lithgow-Berelloni AM . Novel antiviral and cytotoxic agent. PCT Int. Pat. Appl. WO 91.04985, April 18, 1991; GB Appl. 89/22,026, September 29, 1989; Chem Abstr 1991; 115: 248086q.
2. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR . In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 1998; 78: 739–744.
3. Faircloth G, Grant W, Nam S, Jimeno J, Manzanares I, Rinehart K . Schedule-dependency of aplidine, a marine depsipeptide with antitumor activity. Proc Am Assoc Cancer Res 1999; 40: 394.
4. Paz-Ares L, Anthony A, Pronk L, Twelves C, Alonso S, Cortes-Funes H et al. Phase I clinical and pharmacokinetic study of aplidine, a new marine didemnin, administered as 24-hour infusion weekly. Clin Cancer Res 2000; 6(Suppl): 4509.
5. Raymond E, Ady-Vago N, Baudin E, Ribrag V, Faivre S, Lecot F et al. A phase I and pharmacokinetic study of aplidine given as a 24-hour continuous infusion every other week in patients with solid tumor and lymphoma. Clin Cancer Res 2000; 6(Suppl): 4510.